
A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India's largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries'.
该公司进入各个市场的顺序 — 从最早到最新
注册以查看完整信号动态
Alkem Laboratories Ltd. 的国际扩张与竞争对手的对比情况
条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
Alkem Laboratories Ltd.你 | 0 | 0 | 0% | 0 | 32 |
Assistant Manager - Admin/Facility Management
查看职位Mumbai, Maharashtra, India · 3天前
Human Resource Business Partner
查看职位Mumbai, Maharashtra, India · 上周
Product Manager - International Business
查看职位Navi Mumbai, Maharashtra, India · 上周
没有进行中的营销活动
注册以跟踪该公司,并在发生变化时第一时间获得提醒。
印度制药市场11月同比增长9.9%,主要由新产品推出和价格上涨推动。大多数疗法领域呈现健康增长,皮肤科领先,增长15.8%。
值得关注的股票包括塔塔电力、鲁平制药、RVNL、NLC印度、ICICI保诚人寿和Alkem实验室。塔塔电力报告利润增加,鲁平制药澄清了一种通用HIV药物的FDA批准状态。
2025年2月7日,包括LIC、NHPC、Ola Electric、Mazagon Dock、Delhivery和M&M在内的230多家公司将公布第三季度财报。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Alkem Laboratories Ltd. 的业务、市场和增长信号的快速解答。
